PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
PanTera, an IBA and SCK CEN joint venture, aims to secure the large-scale production of actinium-225 (225Ac), which is one of the most promising alpha-emitting radioisotopes to fight cancer. The funds raised will be used primarily toward the construction of a state-of-the-art production facility in Belgium. This facility will not only enable large-scale production, it will also help fulfill PanTera’s ultimate goal to improve the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.
Oaklins’ team in Belgium acted as the sole financial advisor in this transaction.
Contacter l'équipe de la transaction
Cédric Michils
Oaklins KBC Securities
Bart Delusinne
Oaklins KBC Securities
Michaël Rixhon
Oaklins KBC Securities
Robin Bundervoet
Oaklins KBC Securities
Transactions connexes
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
En apprendre plusMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
En apprendre plusQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
En apprendre plus